Apyx medical corporation reports fourth quarter and full year 2023 financial results; introduces full year 2024 financial outlook

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (“apyx medical;” the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today reported financial results for its fourth quarter and full year ended december 31, 2023, and introduced financial expectations for the full year ending december 31, 2024. fourth quarter 2023 financial summary: total revenue of $14.7 million, an increase of 16% year-over-year.
APYX Ratings Summary
APYX Quant Ranking